178 related articles for article (PubMed ID: 37027797)
1. ASCO Policy Statement on Biosimilar and Interchangeable Products in Oncology.
Rodriguez G; Mancuso J; Lyman GH; Cardoso F; Nahleh Z; Vose JM; Gralow JR; Francisco M; Sherwood S
JCO Oncol Pract; 2023 Jul; 19(7):411-419. PubMed ID: 37027797
[TBL] [Abstract][Full Text] [Related]
2. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
[TBL] [Abstract][Full Text] [Related]
3. Use of Biosimilar Medications in Oncology.
Nahleh Z; Lyman GH; Schilsky RL; Peterson DE; Tagawa ST; Chavez-MacGregor M; Rumble RB; Gupta S
JCO Oncol Pract; 2022 Mar; 18(3):177-186. PubMed ID: 35041524
[TBL] [Abstract][Full Text] [Related]
4. Biosimilars in Oncology in the United States: A Review.
Nabhan C; Parsad S; Mato AR; Feinberg BA
JAMA Oncol; 2018 Feb; 4(2):241-247. PubMed ID: 28727871
[TBL] [Abstract][Full Text] [Related]
5. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
Cuellar S; McBride A; Medina P
Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
[TBL] [Abstract][Full Text] [Related]
6. American Society of Clinical Oncology Statement: Biosimilars in Oncology.
Lyman GH; Balaban E; Diaz M; Ferris A; Tsao A; Voest E; Zon R; Francisco M; Green S; Sherwood S; Harvey RD; Schilsky RL
J Clin Oncol; 2018 Apr; 36(12):1260-1265. PubMed ID: 29443651
[TBL] [Abstract][Full Text] [Related]
7. Identification of Barriers Preventing Biosimiliar Oncology Medication Adoption.
Hair J; Maryon T; Lieneck C
Medicina (Kaunas); 2022 Oct; 58(11):. PubMed ID: 36363490
[TBL] [Abstract][Full Text] [Related]
8. The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions.
Bennett CL; Nagai S; Bennett AC; Hoque S; Nabhan C; Schoen MW; Hrushesky WJ; Luminari S; Ray P; Yarnold PR; Witherspoon B; Riente J; Bobolts L; Brusk J; Tombleson R; Knopf K; Fishman M; Yang YT; Carson KR; Djulbegovic B; Restaino J; Armitage JO; Sartor OA
Oncologist; 2021 Aug; 26(8):e1418-e1426. PubMed ID: 33586299
[TBL] [Abstract][Full Text] [Related]
9. Regulation of biosimilar medicines and current perspectives on interchangeability and policy.
O'Callaghan J; Barry SP; Bermingham M; Morris JM; Griffin BT
Eur J Clin Pharmacol; 2019 Jan; 75(1):1-11. PubMed ID: 30187103
[TBL] [Abstract][Full Text] [Related]
10. Opportunities and challenges in biosimilar uptake in oncology.
Dolan C
Am J Manag Care; 2018 Jun; 24(11 Suppl):S237-S243. PubMed ID: 29957909
[TBL] [Abstract][Full Text] [Related]
11. Biosimilars 101: considerations for U.S. oncologists in clinical practice.
Camacho LH; Frost CP; Abella E; Morrow PK; Whittaker S
Cancer Med; 2014 Aug; 3(4):889-99. PubMed ID: 24810680
[TBL] [Abstract][Full Text] [Related]
12. Biosimilars: Implications for Clinical Practice.
Rifkin RM; Peck SR
J Oncol Pract; 2017 Sep; 13(9_suppl):24s-31s. PubMed ID: 28898593
[TBL] [Abstract][Full Text] [Related]
13. US rheumatologists' beliefs and knowledge about biosimilars: a survey.
Gibofsky A; McCabe D
Rheumatology (Oxford); 2021 Feb; 60(2):896-901. PubMed ID: 33146388
[TBL] [Abstract][Full Text] [Related]
14. Current market and regulatory landscape of biosimilars.
Bhatt V
Am J Manag Care; 2018 Nov; 24(21 Suppl):S451-S456. PubMed ID: 30452213
[TBL] [Abstract][Full Text] [Related]
15. Statistical Considerations in Evaluating a Biosimilar Product in an Oncology Clinical Study.
He K; Chen H; Gwise T; Casak S; Lemery S; Keegan P; Pazdur R; Sridhara R
Clin Cancer Res; 2016 Nov; 22(21):5167-5170. PubMed ID: 27582485
[TBL] [Abstract][Full Text] [Related]
16. A Clinical Review of Biosimilars Approved in Oncology.
Ngo D; Chen J
Ann Pharmacother; 2021 Mar; 55(3):362-377. PubMed ID: 32715722
[TBL] [Abstract][Full Text] [Related]
17. Understanding State Regulation of Biosimilars and Effect on Prescribers.
Yale K; Awosika O; Rengifo-Pardo M; Ehrlich A
J Drugs Dermatol; 2017 Oct; 16(10):995-1000. PubMed ID: 29036253
[TBL] [Abstract][Full Text] [Related]
18. Approval Process: An Overview of Biosimilars in the Oncology Setting.
Sowinski-Raff L
Clin J Oncol Nurs; 2018 Oct; 22(5):13-18. PubMed ID: 30239527
[TBL] [Abstract][Full Text] [Related]
19. Prescriber Perspectives on Biosimilar Adoption and Potential Role of Clinical Pharmacology: A Workshop Summary.
Shubow S; Sun Q; Nguyen Phan AL; Hammell DC; Kane M; Lyman GH; Gibofsky A; Lichtenstein GR; Bloomgarden Z; Cross RK; Yim S; Polli JE; Wang YM
Clin Pharmacol Ther; 2023 Jan; 113(1):37-49. PubMed ID: 36251545
[TBL] [Abstract][Full Text] [Related]
20. Sustainable Integration of US Food and Drug Administration-Approved Biosimilars: Pharmacy- Versus Physician-Driven Change.
Waterhouse DM; Ward P; Drosick DR; Burdette C; Davies D; Mendenhall MA
JCO Oncol Pract; 2023 Nov; 19(11):1053-1057. PubMed ID: 37738533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]